Affimed N.V. (0HL9.L)
USD 0.98
(-10.93%)
USD 0.98
(-10.93%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 19.35 Million EUR | 6.39% |
| 2022 | 18.18 Million EUR | -2.69% |
| 2021 | 18.69 Million EUR | 1341.09% |
| 2020 | 1.29 Million EUR | -59.3% |
| 2019 | 3.18 Million EUR | -33.23% |
| 2018 | 4.77 Million EUR | -33.42% |
| 2017 | 7.16 Million EUR | 56.19% |
| 2016 | 4.59 Million EUR | 0.31% |
| 2015 | 4.57 Million EUR | 17.48% |
| 2014 | 3.89 Million EUR | -18.85% |
| 2013 | 4.8 Million EUR | -93.47% |
| 2012 | 73.5 Million EUR | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 14.51 Million EUR | -9.68% |
| 2024 Q1 | 16.07 Million EUR | -16.95% |
| 2023 Q3 | 21.07 Million EUR | 38.24% |
| 2023 Q4 | 19.35 Million EUR | -8.18% |
| 2023 FY | 19.35 Million EUR | 6.39% |
| 2023 Q1 | 16.72 Million EUR | -8.07% |
| 2023 Q2 | 15.24 Million EUR | -8.83% |
| 2022 FY | 18.18 Million EUR | -2.69% |
| 2022 Q1 | 18.63 Million EUR | -0.32% |
| 2022 Q3 | 18.72 Million EUR | -0.36% |
| 2022 Q4 | 18.18 Million EUR | -2.88% |
| 2022 Q2 | 18.79 Million EUR | 0.88% |
| 2021 Q1 | 11.3 Million EUR | 771.47% |
| 2021 FY | 18.69 Million EUR | 1341.09% |
| 2021 Q4 | 18.69 Million EUR | 67.68% |
| 2021 Q3 | 11.14 Million EUR | -0.85% |
| 2021 Q2 | 11.24 Million EUR | -0.54% |
| 2020 Q2 | 1.81 Million EUR | -22.13% |
| 2020 FY | 1.29 Million EUR | -59.3% |
| 2020 Q1 | 2.33 Million EUR | -26.83% |
| 2020 Q4 | 1.29 Million EUR | -45.69% |
| 2020 Q3 | 2.38 Million EUR | 31.5% |
| 2019 Q3 | 3.78 Million EUR | -15.76% |
| 2019 Q2 | 4.49 Million EUR | -3.81% |
| 2019 Q1 | 4.67 Million EUR | -2.03% |
| 2019 FY | 3.18 Million EUR | -33.23% |
| 2019 Q4 | 3.18 Million EUR | -15.89% |
| 2018 Q3 | 5.32 Million EUR | -10.5% |
| 2018 Q2 | 5.95 Million EUR | -9.34% |
| 2018 Q1 | 6.56 Million EUR | -8.43% |
| 2018 FY | 4.77 Million EUR | -33.42% |
| 2018 Q4 | 4.77 Million EUR | -10.4% |
| 2017 Q3 | 7.18 Million EUR | 2.1% |
| 2017 Q4 | 7.16 Million EUR | -0.18% |
| 2017 FY | 7.16 Million EUR | 56.19% |
| 2017 Q2 | 7.03 Million EUR | 50.01% |
| 2017 Q1 | 4.68 Million EUR | 2.16% |
| 2016 FY | 4.59 Million EUR | 0.31% |
| 2016 Q3 | 3.64 Million EUR | -14.8% |
| 2016 Q2 | 4.27 Million EUR | -3.43% |
| 2016 Q1 | 4.42 Million EUR | -3.21% |
| 2016 Q4 | 4.59 Million EUR | 25.96% |
| 2015 FY | 4.57 Million EUR | 17.48% |
| 2015 Q3 | 4.37 Million EUR | 0.83% |
| 2015 Q2 | 4.33 Million EUR | -3.79% |
| 2015 Q1 | 4.5 Million EUR | 15.74% |
| 2015 Q4 | 4.57 Million EUR | 4.64% |
| 2014 Q1 | 4.97 Million EUR | 3.67% |
| 2014 Q3 | 3.8 Million EUR | -26.24% |
| 2014 Q4 | 3.89 Million EUR | 2.47% |
| 2014 Q2 | 5.15 Million EUR | 3.56% |
| 2014 FY | 3.89 Million EUR | -18.85% |
| 2013 Q4 | 4.8 Million EUR | 0.0% |
| 2013 FY | 4.8 Million EUR | -93.47% |
| 2012 FY | 73.5 Million EUR | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Editas Medicine, Inc. | 36.53 Million USD | 47.036% |
| Dynavax Technologies Corporation | 256.91 Million USD | 92.468% |
| Cara Therapeutics, Inc. | 43.16 Million USD | 55.172% |
| Walgreens Boots Alliance, Inc. | 9.55 Billion USD | 99.797% |
| Supernus Pharmaceuticals, Inc. | 41.52 Million USD | 53.401% |
| Perrigo Company plc | 4.07 Billion USD | 99.525% |
| Atara Biotherapeutics, Inc. | 57.87 Million USD | 66.562% |
| Illumina, Inc. | 2.26 Billion USD | 99.145% |
| Thermo Fisher Scientific Inc. | 34.91 Billion USD | 99.945% |
| Nektar Therapeutics | 230.4 Million USD | 91.601% |
| Iovance Biotherapeutics, Inc. | 1 Million USD | -1835.1% |
| IQVIA Holdings Inc. | 14.23 Billion USD | 99.864% |
| Heron Therapeutics, Inc. | 173.75 Million USD | 88.863% |
| Unity Biotechnology, Inc. | 26.99 Million USD | 28.303% |
| BioMarin Pharmaceutical Inc. | 1.13 Billion USD | 98.293% |
| Waters Corporation | 2.35 Billion USD | 99.178% |
| Biogen Inc. | 7.33 Billion USD | 99.736% |
| Sangamo Therapeutics, Inc. | 38.1 Million USD | 49.215% |
| Adicet Bio, Inc. | 17.7 Million USD | -9.309% |
| Evolus, Inc. | 126.54 Million USD | 84.708% |
| bluebird bio, Inc. | 330.32 Million USD | 94.142% |
| Aclaris Therapeutics, Inc. | 3.07 Million USD | -529.506% |
| Esperion Therapeutics, Inc. | 540.94 Million USD | 96.423% |
| FibroGen, Inc. | 170.45 Million USD | 88.647% |
| Agilent Technologies, Inc. | 2.73 Billion USD | 99.292% |
| Homology Medicines, Inc. | 44.05 Million USD | 56.074% |
| Geron Corporation | 85.89 Million USD | 77.472% |
| Alnylam Pharmaceuticals, Inc. | 2.39 Billion USD | 99.193% |
| Corbus Pharmaceuticals Holdings, Inc. | 20.88 Million USD | 7.342% |
| Amicus Therapeutics, Inc. | 445.05 Million USD | 95.652% |
| Myriad Genetics, Inc. | 145 Million USD | 86.654% |
| Regeneron Pharmaceuticals, Inc. | 2.7 Billion USD | 99.284% |
| OPKO Health, Inc. | 326.56 Million USD | 94.074% |
| Viking Therapeutics, Inc. | 1.26 Million USD | -1435.794% |
| Intellia Therapeutics, Inc. | 115.34 Million USD | 83.224% |
| Zoetis Inc. | 6.8 Billion USD | 99.716% |
| Abeona Therapeutics Inc. | 4.4 Million USD | -339.596% |
| Mettler-Toledo International Inc. | 2.16 Billion USD | 99.107% |
| Exelixis, Inc. | 189.94 Million USD | 89.812% |
| Vertex Pharmaceuticals Incorporated | 808.4 Million USD | 97.606% |
| uniQure N.V. | 138.4 Million USD | 86.019% |
| Kala Pharmaceuticals, Inc. | 36.32 Million USD | 46.725% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Axsome Therapeutics, Inc. | 186.37 Million USD | 89.617% |
| Verastem, Inc. | 41.55 Million USD | 53.435% |
| Imunon, Inc. | 1.13 Million USD | -1598.51% |
| Ionis Pharmaceuticals, Inc. | 1.45 Billion USD | 98.669% |
| Sarepta Therapeutics, Inc. | 1.39 Billion USD | 98.615% |
| Neurocrine Biosciences, Inc. | 428.4 Million USD | 95.483% |
| Corcept Therapeutics Incorporated | 151 Thousand USD | -12715.232% |
| Halozyme Therapeutics, Inc. | 1.49 Billion USD | 98.709% |
| TG Therapeutics, Inc. | 110.79 Million USD | 82.534% |
| Blueprint Medicines Corporation | 774.12 Million USD | 97.5% |
| Insmed Incorporated | 1.2 Billion USD | 98.393% |
| Agios Pharmaceuticals, Inc. | 56.98 Million USD | 66.044% |
| Incyte Corporation | 38.28 Million USD | 49.458% |
| Emergent BioSolutions Inc. | 877.5 Million USD | 97.795% |